Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
Prevalence of thyroid disorders in patients with immune thrombocytopenic purpura and its impact on treatment
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
ITP patients will be classified as newly diagnosed, persistent and chronic based on duration less than 3 months, 3-12 months, and more than 12 months respectively.
refractory ITP patients.
Disqualifiers
patients with history of thyroidectomy
patients with history of drug induced ITP
patients with history of HCV, HBV and HIV infection.
Patients who refuse to contribute in this study.
Trial population
prospective cross sectional study
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
Search for thyroid disorders
Diagnostic testTSH , FT3 , FT4
Laboratory test
Diagnostic testSearch for anti thyroid antibodies
Steroid and eltrombopage
DrugSee when we treat thyroid disorders, will patient respond to steroid or eltrombopage?
Treatment groups
100 Participants
are divided into 1 treatment groupGroup A: Patients known ITP3 interventions
Trial outcomes
Primary outcomes
1
Assess the frequency of thyroid disorders in patients with IT
Screening of thyroid disorders in patients with ITP
Time frame
Assess the frequency of thyroid disorders in patients with IT2
Evaluate the treatment of thyroid disorders in improvement in platelets count.
Evaluate if patients have managed according to thyroid disorders, will this affect in their response to ITP management
Time frame
Evaluate the treatment of thyroid disorders in improvement in platelets count.Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: